It was previously shown that breast cancer patients with UGT2B7-161 TT or CT had increased epirubicin clearance rate (median, 134.0 L/h; p = 0.002) compared to the patients with UGT2B7-161 CC (median, 103.3 L/h) [236]. This evidence concerns the gene UGT2B7 and breast cancer.